Christophe dombu
Stock Analyst at Kepler Capital
(0.19)
# 4,190
Out of 4,334 analysts
184
Total ratings
38.7%
Success rate
-9.7%
Average return
Main Sectors:
Stocks Rated by Christophe dombu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: 0QBO Coloplast A/S | Initiated Coverage: Buy | $482 | $405.36 | +18.91% | 1 | May 20, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | $810 | $697.71 | +16.09% | 33 | May 7, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Sell | $24 | $24.00 | -2.08% | 19 | May 7, 2026 | |
| LON: SN Smith & Nephew plc | Maintained: Buy | $1,462 | $1,138.00 | +28.47% | 5 | May 6, 2026 | |
| EPA: VIRP Virbac SA | Maintained: Buy | $415 | $362.50 | +14.48% | 6 | Apr 17, 2026 | |
| SWX: KURN Kuros Biosciences AG | Maintained: Buy | $38 | $21.76 | +74.63% | 9 | Apr 14, 2026 | |
| SWX: BSLN Basilea Pharmaceutica AG | Maintained: Buy | $69 → $70 | $53.30 | +31.33% | 27 | Apr 13, 2026 | |
| LON: 0HNZ Fagron NV | Maintained: Buy | $28 | $25.15 | +9.34% | 2 | Apr 9, 2026 | |
| EPA: MAAT MaaT Pharma SA | Maintained: Buy | $17 | $3.17 | +436.28% | 26 | Mar 31, 2026 | |
| FRA: 52U Hyloris Pharmaceuticals SA | Maintained: Buy | $14 | $4.88 | +193.03% | 25 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $2.87 | +265.85% | 26 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $0.1 → $0.01 | $0.1834 | n/a | 5 | Feb 7, 2025 |
Coloplast A/S
May 20, 2026
Initiated Coverage: Buy
Price Target: $482
Current: $405.36
Upside: +18.91%
argenx SE
May 7, 2026
Maintained: Buy
Price Target: $810
Current: $697.71
Upside: +16.09%
Lakefront Biotherapeutics NV
May 7, 2026
Maintained: Sell
Price Target: $24
Current: $24.00
Upside: -2.08%
Smith & Nephew plc
May 6, 2026
Maintained: Buy
Price Target: $1,462
Current: $1,138.00
Upside: +28.47%
Virbac SA
Apr 17, 2026
Maintained: Buy
Price Target: $415
Current: $362.50
Upside: +14.48%
Kuros Biosciences AG
Apr 14, 2026
Maintained: Buy
Price Target: $38
Current: $21.76
Upside: +74.63%
Basilea Pharmaceutica AG
Apr 13, 2026
Maintained: Buy
Price Target: $69 → $70
Current: $53.30
Upside: +31.33%
Fagron NV
Apr 9, 2026
Maintained: Buy
Price Target: $28
Current: $25.15
Upside: +9.34%
MaaT Pharma SA
Mar 31, 2026
Maintained: Buy
Price Target: $17
Current: $3.17
Upside: +436.28%
Hyloris Pharmaceuticals SA
Mar 26, 2026
Maintained: Buy
Price Target: $14
Current: $4.88
Upside: +193.03%
Mar 20, 2026
Maintained: Buy
Price Target: $11
Current: $2.87
Upside: +265.85%
Feb 7, 2025
Downgraded: Sell
Price Target: $0.1 → $0.01
Current: $0.1834
Upside: n/a